Mylan Asks Supreme Court To Rein In 'Tactical' Drug Patenting
Mylan Inc. and other generic drug companies have asked the U.S. Supreme Court to review a Federal Circuit decision that upheld a UCB Inc. patent on epilepsy drug Vimpat, telling the...To view the full article, register now.
Already a subscriber? Click here to view full article